Analysts have been eager to weigh in on the Healthcare sector with new ratings on Evaxion Biotech (EVAX – Research Report), 60 Degrees Pharmaceuticals, Inc. (SXTP – Research Report) and Genprex (GNPX – Research Report).
Evaxion Biotech (EVAX)
H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Evaxion Biotech today and set a price target of $14.00. The company’s shares closed last Tuesday at $3.88, close to its 52-week low of $2.82.
According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Evaxion Biotech with a $11.00 average price target, representing a 223.5% upside. In a report released yesterday, Ladenburg Thalmann & Co. also upgraded the stock to Buy with a $8.00 price target.
See the top stocks recommended by analysts >>
60 Degrees Pharmaceuticals, Inc. (SXTP)
60 Degrees Pharmaceuticals, Inc. received a Hold rating from H.C. Wainwright analyst Edward White today. The company’s shares closed last Tuesday at $0.28, close to its 52-week low of $0.22.
According to TipRanks.com, White has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The the analyst consensus on 60 Degrees Pharmaceuticals, Inc. is currently a Hold rating.
Genprex (GNPX)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Genprex today and set a price target of $10.00. The company’s shares closed last Tuesday at $2.84, close to its 52-week low of $2.50.
According to TipRanks.com, Chen has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Genprex with a $10.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EVAX:
